

**LISTING OF THE CLAIMS**

The following listing of the claims replaces all prior claims in the application:

1. (Currently Amended) A method for inducing T-cell tolerance or non- responsiveness of donor T-cells to desired alloantigen-bearing cells *ex vivo* comprising the following:

- (i) ~~providing a culture containing donor tissue containing donor T-cells purifying CD4<sup>+</sup> T-cells from donor tissue;~~
- (ii) ~~irradiating alloantigen-bearing cells obtained from a recipient to deplete recipient T-cells;~~
- (iii) ~~producing a mixed lymphocyte reaction culture by adding to said donor T-cell culture comprising the purified donor CD4<sup>+</sup> T-cells and irradiated, T-cell depleted alloantigen-bearing cells obtained from a recipient;~~
- (iv) ~~(iv) adding an anti-gp39 antibody to the mixed lymphocyte reaction culture, thereby initiating a mixed lymphocyte reaction culture comprising purified donor CD4<sup>+</sup> T-cells, T-cell depleted recipient alloantigen-bearing cells, and anti-gp39 antibody;~~
- (v) ~~(v) maintaining the mixed lymphocyte reaction culture *ex vivo* for a sufficient time to render the donor CD4<sup>+</sup> T-cells substantially tolerant or non-responsive to said alloantigen-bearing cells, and~~
- (vi) ~~(vi) assaying *ex vivo* for induction of donor CD4<sup>+</sup> T-cell tolerance or non-responsiveness.~~

2. (Currently Amended) The method of Claim 1, wherein the ~~donor tissue containing donor T-cells~~ is donor bone marrow or peripheral blood cells.

3. (Canceled)

4. (Previously Presented) The method of Claim 1, wherein the gp39 antibody is an anti-human gp39 monoclonal antibody.

5. (Previously Presented) The method of Claim 4, wherein said anti-gp39 antibody is a chimeric or humanized anti-human gp39 monoclonal antibody.

6. (Currently Amended) The method of Claim 1, wherein the donor T-cells are cultured in step (iv) for a time ranging from about 4 to 30 days.

7. (Currently Amended) The method of Claim 6, wherein said ~~time ranges from about 5 to 15~~ donor T-cells are cultured in step (v) for a time ranging from 6 to 10 days.

8. (Canceled) The method of Claim 1, wherein the alloantigen-bearing cells have been treated to deplete recipient T-cells.

9. (Canceled) The method of Claim 8, wherein recipient T-cell depletion is effected by irradiation.

10. (Previously Presented) The method of Claim 1, wherein the donor T-cells that have been determined to be tolerized by the assay of step (vi) are transplanted into a recipient in need of such transplantation.

11. (Original) The method of Claim 10, wherein the recipient is in need of immune reconstitution as a result of disease or disease treatment.

12. (Canceled)

13. (Previously Presented) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring IL-2 concentration in the cell culture medium supernatants of the donor T-cells cultured in step (v) and of control donor T-cells, wherein detection of reduced IL-2 concentration in the supernatant of the donor T-cells cultured in step (v), relative to the IL-2 concentration in the supernatant of control T-cells, is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

14. (Withdrawn) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring the concentration of interferon-gamma in the cell culture medium supernatants of the donor T-cells cultured in step (v) and of control donor T-cells,

wherein detection of reduced interferon-gamma concentration in the supernatant of the donor T-cells cultured in step (v) relative to that of the control T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

15. (Withdrawn) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises assaying to detect at least one antigen selected from the group consisting of L-selectin, ICAM-1, and CD45 in the donor T-cells cultured in step iv and control donor T-cells,

wherein detection of an increased amount of L-selectin or ICAM-1, or a reduced amount of CD45 in the donor T-cells cultured in step (v) relative to that in the control donor T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.